Apricus Biosciences Inc (APRI)

0.33
0.03 8.40
NASDAQ : Health Care
Prev Close 0.36
Open 0.35
Day Low/High 0.30 / 0.36
52 Wk Low/High 0.32 / 1.99
Volume 677.88K
Avg Volume 424.20K
Exchange NASDAQ
Shares Outstanding 61.81M
Market Cap 20.40M
EPS -0.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Apricus Biosciences Provides Corporate Update And First Quarter Financial Results

Apricus Biosciences Provides Corporate Update And First Quarter Financial Results

Vitaros® U.S. NDA Re-Submission on Schedule for 3Q 2016

Apricus Biosciences Announces Year-End 2015 Update And 2016 Growth Strategy

Apricus Biosciences Announces Year-End 2015 Update And 2016 Growth Strategy

Top-Line Phase 2b Data for Fispemifene Expected in Q1

Apricus Biosciences And Ferring Pharmaceuticals Sign Exclusive Distribution Agreement To Market Topical Erectile Dysfunction Cream Vitaros(TM) In Latin American Countries

Apricus Biosciences And Ferring Pharmaceuticals Sign Exclusive Distribution Agreement To Market Topical Erectile Dysfunction Cream Vitaros(TM) In Latin American Countries

Apricus Eligible to Receive Up to $18.25 Million in Upfront and Milestone Payments, in Addition to Royalties on Net Sales

Apricus Reports Top-Line Phase 2a Data For RayVa(TM), Its Topical Treatment For Raynaud's Phenomenon

Apricus Reports Top-Line Phase 2a Data For RayVa(TM), Its Topical Treatment For Raynaud's Phenomenon

Apricus Reaffirms Plans to Move RayVa Into Late-Stage Clinical Trials in Patients With Scleroderma Who Also Suffer From Raynaud's Phenomenon

Apricus Biosciences (ARPI) Stock Climbs Following Allergan License Agreement

Apricus Biosciences (ARPI) Stock Climbs Following Allergan License Agreement

Apricus Biosciences (ARPI) shares are rising after it agreed to a license agreement with Allergan (AGN) for the U.S. rights to Vitaros.

Apricus Biosciences Enters Into License Agreement With Allergan For The U.S. Rights To Vitaros(TM)

Apricus Biosciences Enters Into License Agreement With Allergan For The U.S. Rights To Vitaros(TM)

Apricus to Lead Clinical and Regulatory Efforts; Allergan Retains Commercialization Option in U.S.

Apricus Biosciences Announces Approval Of Vitaros(R) For The Treatment Of Erectile Dysfunction In Twelve Additional Countries

Apricus Biosciences Announces Approval Of Vitaros(R) For The Treatment Of Erectile Dysfunction In Twelve Additional Countries

Vitaros Now Approved in Twenty-Two Countries in Europe Under the Decentralized Procedure